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Background. Antiretroviral therapy in human immunodeﬁciency virus (HIV)-infected women and blacks merits particular
scrutiny because these groups have been underrepresented in clinical trials.
Methods. To document the effects of raltegravir across sex and racial lines, we conducted a pooled subgroup analysis of the
efﬁcacy and safety of raltegravir 400 mg BID plus tenofovir-emtricitabine by sex (women vs men) and self-identiﬁed race (black
vs non-black) using phase 3 studies in treatment-naive patients.
Results. Study participants included 42 black women, 102 non-black women, 48 black men, and 477 non-black men. Clade B
infections were less common in women (43.8%) than men (84.6%) and in blacks (45.6%) than non-blacks (80.5%). Baseline CD4
counts were≤200 cells/µL in 52.2% of blacks and 31.6% of non-blacks. Black men had the largest proportion of patients with baseline
CD4 counts <50 cells/µL and the highest nontreatment-related discontinuation rate among the 4 sex-by-race subgroups. Human
immunodeﬁciency virus-ribonucleic acid levels <50 copies/mL were achieved at week 48 in 92.7% (95% conﬁdence interval [CI],
80.1–98.5) of black women, 93.6% (95% CI, 86.6–97.6) of non-black women, 82.9% (95% CI, 67.9–92.8) of black men, and
91.4% (95% CI, 88.4–93.8) of non-black men. Serious clinical adverse events were reported in 9.0% of women versus 8.8% of
men and in 11.1% of blacks versus 8.5% of non-blacks.
Conclusions. In this post hoc analysis of patients with previously untreated HIV-1 infection receiving raltegravir plus tenofovir-
emtricitabine, generally comparable results were achieved across sex and racial subgroups. However, black men had a lower response
rate than either black women or non-black men, partially attributable to lower baseline CD4 counts and higher discontinuation rates.
Keywords. QDMRK; raltegravir; STARTMRK; subgroup analyses.
Human immunodeﬁciency virus (HIV) infection continues to
present major public health challenges in both developing
and developed nations. According to the World Health Organi-
zation [1], there were over 1 million deaths from HIV-related
causes and approximately 2 million new infections in 2014.
The enduring burden of HIV in women, including mother-
to-child transmission, was late to be recognized and remains
inadequately addressed. Currently for women in their re-
productive years, HIV is the leading cause of death worldwide
[1]. The response to HIV infection was especially slow to be ad-
dressed in women and minority populations. This blunted early
response to the global HIV epidemic continues to exact an im-
mense toll on women and blacks, particularly in sub-Saharan
Africa where most new HIV infections are occurring. Dispari-
ties in care persist in resource-constrained regions of the world
as well as in industrialized countries such as the United States
[2, 3].Underserved populations consisting disproportionately of
poor blacks and women now constitute the large majority of
people living with HIV around the globe [1–3].
Although drug side-effects may be different and sometimes
more prominent in women than men, the efﬁcacy of antiretro-
viral regimens has been thought to be reasonably comparable in
both sexes [3–9]. For example, women report more nausea and
less diarrhea than men [9]. On the other hand, lower response
rates have been reported in black patients relative to whites or
Asians [9–11]. For example, at week 48 in treatment-naive,
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HIV-1-infected patients enrolled in the phase 3 ECHO and
THRIVE trials, sex differences in efﬁcacy were not apparent,
whereas response rates were lower among black compared
with non-black patients irrespective of treatment [9].
Emerging data from the recently completed noninferiority
Women Antiretroviral Efﬁcacy and Safety (WAVES) study sug-
gest that not all regimens in common use among women are
equivalent. This as-yet unpublished landmark trial exclusively
enrolled 575 treatment-naive women from 80 sites around the
world, comparing a single-pill combination of tenofovir,
emtricitabine, and elvitegravir boosted with cobicistat to teno-
fovir-emtricitabine plus ritonavir-boosted atazanavir [12]. Non-
inferiority was ﬁrst established, and then superiority of the
elvitegravir arm was sequentially inferred. The difference in
response rates between regimens was not fully explained by
differential medication adherence in the study arms.
Raltegravir, as part of combination antiretroviral therapy, has
proven efﬁcacious and well tolerated in most HIV-1 infected
patients without obvious differences among sex or racial sub-
groups [13–16]. In individual randomized trials, responses in
women and blacks treated with raltegravir appeared to be
similar to the results observed in other demographic groups
[13–17]. Likewise, comparable efﬁcacy across sex and racial
lines was observed in REALMRK, an international, open-
label, single-arm study of raltegravir-based therapy speciﬁcally
designed to generate data for HIV-positive patients traditionally
underrepresented in pivotal clinical trials [18].
In the phase 3 STARTMRK study of treatment-naive
patients, the overall efﬁcacy of raltegravir was at least noninfe-
rior to the results with efavirenz when used in combination with
tenofovir-emtricitabine through 5 years of therapy, including at
the primary endpoint of 48 weeks [15, 16]. QDMRK was a later
noninferiority trial of treatment-naive patients comparing the
standard raltegravir dosage of 400 mg BID to an 800 mg QD
schedule, each given with tenofovir-emtricitabine [17]. Nonin-
feriority of once-daily dosing with the standard formulation of
raltegravir was not demonstrated relative to the approved twice-
daily regimen at the primary 48-week endpoint. The safety and
efﬁcacy results from these large trials did not appear to vary by
sex or race. However, the numbers of participants from under-
studied populations in each randomized controlled study were
small relative to the proportions of white men enrolled [19].
To better document responses to raltegravir along sex and
racial lines, we conducted a pooled subgroup analysis of the
efﬁcacy and safety of raltegravir 400 mg BID combined with
tenofovir-emtricitabine by sex (women vs men) and self-
identiﬁed race (black vs non-black) using composite data from
the 2 aforementioned randomized, double-blind, international
studies of treatment-naive HIV-infected patients [15, 17]. Results
through the initial 48 weeks of treatment were chosen for this
post hoc analysis because these data were available from both
studies and week 48 was the primary endpoint in each trial.
METHODS
Parent Study Designs
STARTMRK (MK-0518 Protocol 021; clinicaltrials.gov identiﬁ-
er NCT00369941) and QDMRK (MK-0518 Protocol 071;
clinicaltrials.gov identiﬁer NCT00745823) were international,
blinded, randomized, active-controlled phase 3 clinical trials
[15, 17]. The studies were approved by the institutional review
boards at each participating institution and conducted in accor-
dance with Good Clinical Practice guidelines. All participants
provided written informed consent. The primary analyses for
both studies were performed at week 48 as speciﬁed by protocol.
Previously untreated HIV-1-infected patients ≥18 years of
age were eligible if their viral ribonucleic acid (vRNA) levels
were >5000 copies/mL, and the isolated virus was susceptible
to all study drugs at entry. Patients were stratiﬁed by screening
vRNA levels and viral hepatitis coinfection status. After stratiﬁ-
cation, patients were randomly assigned in a 1:1 ratio to receive
a standard raltegravir or comparator regimen (efavirenz in
STARTMRK and raltegravir 800 mg QD in QDMRK), each in
combination with coformulated tenofovir-emtricitabine.
Human immunodeﬁciency virus RNA levels were measured
by the COBAS Amplicor HIV-1 Monitor assay (version 1.5;
Roche Diagnostics, Branchburg, NJ) with a lower limit of quan-
tiﬁcation of 400 vRNA copies/mL and the Ultrasensitive Am-
plicor HIV-1 Monitor assay (version 1.5; Roche Diagnostics)
with a lower quantiﬁcation limit of 50 vRNA copies/mL.
Statistical Analyses
For STARTMRK and QDMRK, all patients treated with raltegra-
vir 400 mg BID combined with tenofovir-emtricitabine were in-
cluded in the primary analyses at week 48. For calculation of
virologic response rates, the protocols stipulated that the primary
approach to handling missing data would be to include all non-
completers as failures (NC = F). The results using the NC = F ap-
proach to missing data only counted patients with vRNA levels
<50 copies/mL at the speciﬁed time point as successes. An ob-
served-failure (OF) approach allowing evaluation of drug efﬁcacy
without confounding by discontinuations due to intolerability or
nontreatment-related reasons was also prespeciﬁed as a second-
ary efﬁcacy analysis as well as for assessing changes in baseline
CD4 cell counts and for the planned subgroup efﬁcacy analyses
based on demographic and prognostic factors at baseline.
In the current pooled subgroup analysis, patients who had
self-identiﬁed as multiracial were included as non-blacks. The
proportion of patients with vRNA levels <50 copies/mL and
the mean change from baseline CD4 cell counts at week 48
were summarized by sex and race with 95% exact conﬁdence
intervals (CIs). For between-subgroup differences, 95% CIs
were calculated by the method of Miettinen and Nurminen
[20] with weights proportional to the size of each stratum.
Both the NC = F and OF approaches were used for missing
vRNA results in parallel analyses. With the OF approach,
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patients who discontinued for lack of efﬁcacy were counted as
failures thereafter and their baseline CD4 cell counts were car-
ried forward to week 48, whereas patients discontinuing pre-
maturely for other reasons were not included at subsequent
time points. Recognizing the potential of confounding by co-
variates (such as region of origin and infecting clade), inter-
action effects between sex and race on response rates were
tested by a logistic model as an exploratory analysis.
All reported adverse events occurring while on treatment
or in the 14 days after discontinuation of therapy during
the initial 48 weeks of each study were included in the present
analysis. Clinical and laboratory adverse events and worsen-
ing grades for prespeciﬁed laboratory parameters were tallied.
Adverse events were considered to be drug related when
judged by the site investigator as deﬁnitely, probably, or pos-
sibly related to any of the study drugs. The intensity of clin-
ical adverse events was rated by the investigator as mild,
moderate, or severe. The severity of laboratory abnormalities
was graded according to the 1992 DAIDS toxicity guidelines
for adults.
RESULTS
Baseline Characteristics and Patient Accounting
Of the 669 patients who received raltegravir 400 mg BID
in STARTMRK and QDMRK, 144 (21.5%) were women (mean
age, 38.5 years) and 525 (78.5%) were men (mean age, 38.0
years), and 90 (13.5%) were black (mean age, 38.5 years) and
579 (87%) were non-black (mean age, 38.1 years) (Table 1).
Table 1. Baseline Characteristics of Patients Treated With Raltegravir 400 mg BID in the STARTMRK and QDMRK Trials by Sex and Racea
Characteristic
Black Women Non-black Women Black Men Non-black Men
(N = 42) (N = 102) (N = 48) (N = 477)
Study, n (%)
STARTMRK 12 42 21 206
QDMRK 30 60 27 271
Region, n (%)
Latin America 2 (4.8) 34 (33.3) 6 (12.5) 126 (26.4)
Southeast Asia 0 (0.0) 28 (27.5) 0 (0.0) 31 (6.5)
South Africa 16 (38.1) 1 (1.0) 4 (8.3) 2 (0.4)
United States/Canada 12 (28.6) 7 (6.9) 26 (54.2) 129 (27.0)
EU/Australia 12 (28.6) 32 (31.4) 12 (25.0) 189 (39.6)
Age, in years
Mean (SD) 40.1 (10.7) 37.8 (11.6) 37.0 (9.3) 38.1 (9.4)
Median (range) 39.0 (23–71) 35.0 (19–67) 36.0 (20- 63) 38.0 (20–69)
CD4 Cell Count, Cells/µL
Mean (SD) 191.4 (112.7) 240.3 (121.3) 212.4 (146.7) 266.1 (132.9)
Median (range) 189.5 (4–507) 237.5 (2–577) 197.0 (1–555) 260.5 (1–803)
History of AIDS, n (%)
Yes 1 (2.4) 13 (12.7) 5 (10.4) 33 (6.9)
Viral Subtype, n (%)
Clade B 10 (23.8) 53 (52.0) 31 (64.6) 413 (86.6)
Non-Clade B 32 (76.2) 49 (48.0) 17 (35.4) 60 (12.6)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.8)
Viral Hepatitis Status, n (%)
Positive HBV or HCV 2 (4.8) 6 (5.9) 5 (10.4) 30 (6.3)
Baseline Plasma HIV RNA, n (%)
≤50 000 copies/mL 13 (31.0) 45 (44.1) 20 (41.7) 154 (32.3)
>50 000 copies/mL 29 (69.0) 57 (55.9) 28 (58.3) 323 (67.7)
≤100 000 copies/mL 25 (59.5) 62 (60.8) 26 (54.2) 250 (52.4)
>100 000 copies/mL 17 (40.5) 40 (39.2) 22 (45.8) 227 (47.6)
≤500 000 copies/mL 38 (90.5) 95 (93.1) 43 (89.6) 433 (90.8)
>500 000 copies/mL 4 (9.5) 7 (6.9) 5 (10.4) 44 (9.2)
Baseline CD4 Cell Counts, n (%)
≤50 cells/µL 6 (14.3) 10 (9.8) 11 (22.9) 27 (5.7)
>50 to ≤200 cells/µL 17 (40.5) 23 (22.5) 13 (27.1) 123 (25.8)
>200 cells/µL 19 (45.2) 69 (67.6) 24 (50.0) 326 (68.3)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2)
Abbreviations: AIDS, acquired immune deficiency syndrome; EU, European Union; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; N, number of patients in
each group; n (%), number (percentage) of patients in each category; RNA, ribonucleic acid; SD, standard deviation.
a Patients who self-identified as multiracial were included as non-blacks.
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Patients treated in the 2 trials had generally similar baseline char-
acteristics overall, except that patients in STARTMRK had lower
median CD4 counts (212 vs 278 cells/µL) than in QDMRK.
Overall, the female cohort had a lower proportion of white
patients (36.8% vs 63.8%) and higher proportions of black
(29.2% vs 9.1%) and Asian (20.1% vs 7.6%) patients than the
male cohort. Infection with clade B virus was less common
among women (43.8%) than among men (84.6%). Baseline
vRNA levels were >100 000 copies/mL in 39.6% of women
and 47.4% of men (overall means, 4.8 [standard deviation;
SD = 0.6] and 4.9 [SD = 0.6] log10 copies/mL, respectively).
Baseline CD4 cell counts were ≤200 cells/µL in 38.9% of
women and 33.1% of men (overall means, 226.0 [SD = 120.6]
vs 261.1 [SD = 135.0] cells/µL, respectively).
Overall, the black cohort had a higher proportion of women
(46.7%) than the non-black cohort (17.6%). Although the ma-
jority of black men were enrolled in North America (26 of 48
[54.2%] vs 4 of 48 [8.3%] from Africa), the largest number of
black women were South African (16 of 42 [38.1%] vs 12 of
42 [28.6%] African Americans). Infection with clade B virus
was less common among black patients (45.6%) than among
non-black patients (80.5%), likely a consequence of the dispro-
portionate enrollment of the black patients (particularly black
women) from sub-Saharan Africa. Baseline vRNA levels were
>100 000 copies/mL in 43.3% of blacks and 46.1% of non-blacks
(overall means, 4.9 [SD = 0.6] log10 copies/mL for both the
black and non-black subgroups). Baseline CD4 cell counts
were ≤200 cells/µL in 52.2% of blacks and 31.6% of non-
blacks; mean and median CD4 counts at baseline were lower
in the black cohort (202.6 and 193.0 cells/µL, respectively)
than in the non-black cohort (261.5 and 255.0 cells/μL, re-
spectively). The largest proportion of patients with baseline
CD4 counts <50 cells/µL among the 4 sex-by-race subgroups
were black men (22.9%), followed by black women (14.3%).
A total of 91.7% of women and 93.1% of men completed
48 weeks of treatment in both studies (Table 2). Other than
pregnancy, the reasons for discontinuation were comparable
among women and men except that 10 men (1.9%) and no
women were lost to follow up. A total of 90.0% of black patients
and 93.3% of non-black patients completed 48 weeks of treat-
ment. Black patients were more likely to discontinue for reasons
unrelated to treatment than non-black patients; no black patient
discontinued due to lack of efﬁcacy. Among the 4 subgroups,
discontinuation rates were highest for black men (14.6%)—
more than double the rates in either non-black men (6.1%) or
black women (4.8%).
Virologic and Immunologic Responses
Using an OF approach to missing data, generally consistent
virologic and immunologic effects were observed across sex or
racial groups through the initial 48 weeks of therapy (Figure 1).
At week 48, vRNA levels <50 copies/mL were achieved in 93.3%
of women (126 of 135) and 90.7% of men (458 of 505) (differ-
ence: +2.6%; 95% CI,−3.3 to +7.0). The mean change in CD4 cell
count from baseline to week 48 was + 189.1 cells/µL in women
and + 194.4 cells/µL in men (difference: −5.3 cells/µL; 95% CI,
−31.1 to +20.5). At week 48, vRNA levels <50 copies/mL were
achieved in 87.8% of blacks (126 of 135) and 91.8% of non-blacks
(458 of 505) (difference: −4.0%; 95% CI, −13.0 to +2.1). The
mean change in CD4 cell count from baseline to week 48 was
+ 182.4 cells/µL in blacks and + 194.9 cells/µL in non-blacks
(difference: −12.6 cells/µL; 95% CI, −43.9 to +18.8).
Using an OF approach to missing data, vRNA levels <50 cop-
ies/mL were achieved at week 48 in 38 of 41 (92.7%; 95% CI,
80.1–98.5) black women, 88 of 94 (93.6%; 95% CI, 86.6–97.6)
non-black women, 34 of 41 (82.9%; 95% CI, 67.9–92.8) black
men, and 424 of 464 (91.4%; 95% CI, 88.4–93.8) non-black
men; the respective increments in CD4 counts from baseline
were 147.8 (95% CI, 120.5–175.0), 207.4 (95% CI, 181.5–
233.2), 217.0 (95% CI, 168.0–265.9), and 192.4 (95% CI,
179.7–205.0) cells/µL. Of the 4 sex-by-race subgroups, black
men were the least likely to have vRNA levels <50 copies/mL;
this observation was more pronounced with the NC = F than
OF method of handling missing data, likely due to black men
having a higher discontinuation rate unrelated to treatment
than the other subgroups (Tables 3 and 4). A later analysis sep-
arating the 59 patients identifying themselves as multiracial
from those considered as non-black revealed that this subgroup
had numerically higher response rates for both women and men
than other “non-blacks” or “blacks” using either the NC = F
(93.2%; 95% CI, 83.5–98.1) or OF (94.8%; 95% CI, 85.6–98.9)
approaches to missing data. Black men experienced the numer-
ically greatest increment in CD4 cell counts, whereas black
women had the smallest increase.
Safety and Tolerability
The types of adverse events in each of the 4 sex-by-race sub-
groups are shown in Table 5. The causes of the 2 deaths were
reported as Kaposi’s sarcoma at week 8 in a 27-year-old black
man and cerebral hemorrhage at week 13 in 57-year-old
Asian man.














Completed 48 wks 40 (95.2) 92 (90.2) 41 (85.4) 448 (93.9)
Discontinued by week 48 2 (4.8) 10 (9.8) 7 (14.6) 29 (6.1)
Lack of Efficacy 0 (0.0) 1 (1.0) 0 (0.0) 8 (1.7)
Clinical adverse event 0 (0.0) 3 (2.9) 1 (2.1) 6 (1.3)
Consent withdrawn 0 (0.0) 2 (2.0) 0 (0.0) 2 (0.4)
Lost to follow up 0 (0.0) 0 (0.0) 3 (6.3) 7 (1.5)
Protocol deviation 0 (0.0) 1 (1.0) 0 (0.0) 1 (0.2)
Physician decision 0 (0.0) 0 (0.0) 1 (2.1) 3 (0.6)
Pregnancy 1 (2.4) 2 (2.0) 0 (0.0) 0 (0.0)
Other 1 (2.4) 1 (1.0) 2 (4.2) 2 (0.4)
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During the initial 48 weeks of the studies, clinical adverse
events were reported in 123 (85.4%) of the 144 women and
466 (88.8%) of the 525 men and led to treatment disconti-
nuation in 3 (2.1%) women and 8 (1.5%) men. Drug-related
clinical adverse events were reported in 50 (34.7%) women
and 166 (31.6%) men. Serious clinical adverse events were
Table 3. Percentage of Patients With vRNA Level <50 copies/mL at Week 48 by Sex by Race Using the Noncompleter as Failure Approach to Missing Data
Total (Women +Men) Women Men Sex Difference (Women – Men) [95% CI]
Total (black + non-black) 87.3 [84.5 to 89.7] 87.5 [81.0 to 92.4] 87.2 [84.1 to 90.0] 0.3 [−6.6 to 5.8]
Black 80.0 [70.2 to 87.7] 90.5 [77.4 to 97.3] 70.8 [55.9 to 83.0] 19.6 [3.2 to 35.5]
Non-black 88.4 [85.5 to 90.9] 86.3 [78.0 to 92.3] 88.9 [85.7 to 91.6] −2.6 [−11.0 to 3.7]
Race difference (black – non-black) [95% CI] −8.4 [−18.2 to −0.9] 4.2 [−9.5 to 14.4] −18.1 [−32.3 to −6.7] Test for sex-by-race interaction P = .016
Abbreviation: CI, confidence interval; vRNA, viral ribonucleic acid.
Figure 1. Time course of virologic response rate (confirmed viral ribonucleic acid level <50 copies/mL) (A) and CD4 cell count increment from baseline (B). Graphs are
displayed for the 4 sex-by-race subgroups through the initial 48 weeks of the pooled studies. Missing data were handled using an observed-failure approach. Abbreviation:
CI, confidence interval.
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reported in 13 women (9.0%) and 46 men (8.8%). Laboratory
adverse events occurred in 12 (8.3%) women and 51 (9.7%)
men and were considered to be drug related in 4 (2.8%)
women and 17 (3.2%) men. No serious laboratory adverse
events were reported in either group.
Clinical adverse events were reported in 79 (87.8%) of the 90
black patients and 510 (88.1%) of 579 non-black patients, with
treatment discontinuations precipitated by a clinical adverse
event occurring in 1 (1.1%) and 10 (1.7%) patients, respectively.
Drug-related clinical adverse events were reported in 27 (30.0%)
blacks and 189 (32.6%) non-blacks. Serious clinical adverse
events were reported in 10 black patients (11.1%) and 49
non-black patients (8.5%), including 7 (14.6%) of 48 black
men. Laboratory adverse events occurred in 8 (8.9%) black pa-
tients and 55 (9.5%) non-black patients and were considered to
be drug related in 1 (1.1%) black patient and 20 (3.5%) non-
black patients. No serious laboratory adverse events were re-
ported in either group. Decreased absolute neutrophil counts
on therapy were more common among black than non-black
patients (grade 2–4, 17% vs 2%, respectively); other laboratory
changes were generally similar across racial subgroups.
DISCUSSION
The efﬁcacy and safety of antiretroviral therapy in HIV-infected
women and blacks require special attention because these
groups have historically been underrepresented in pivotal clin-
ical trials and underserved around the world [1–3, 19]. The
combined demographics for patients randomized to the ralte-
gravir 400 mg BID arms in STARTMRK and QDMRK indicate
that only 22% were woman and 13% self-identiﬁed as black [15,
17]. Biological and psychosocial factors based on sex or race
could inﬂuence therapeutic responses [7, 10, 11, 21–28].
Generally consistent virologic and immunologic effects with
an overall similar safety proﬁle were maintained across sex and
racial subgroups treated with raltegravir plus tenofovir-emtrici-
tabine. However, some numerical variations were observed in
subpopulations. In the current analysis of treatment-naive pa-
tients, discontinuation rates were higher for black men than
for either non-black men or black women, but these differences
were not attributable to more adverse events or lower efﬁcacy.
The lowest response rates were likewise seen in black men, a
trend also recognized in treatment of hepatitis C infection [29].
Table 4. Percentage of Patients With vRNA Level <50 copies/mL at Week 48 by Sex by Race Using the Observed-Failure Approach to Missing Data
Total (Women +Men) Women Men Sex Difference (Women – Men) [95% CI]
Total (black + non-black) 91.3 [88.8 to 93.3] 93.3 [87.7 to 96.9] 90.7 [87.8 to 93.1] 2.6 [−3.3 to 7.0]
Black 87.8 [78.7 to 94.0] 92.7 [80.1 to 98.5] 82.9 [67.9 to 92.8] 9.8 [−5.0 to 25.3]
Non-black 91.8 [89.2 to 93.9] 93.6 [86.6 to 97.6] 91.4 [88.4 to 93.8] 2.2 [−4.9 to 6.9]
Race difference (black – non-black) [95% CI] −4.0% [−13.0 to 2.1] −0.9% [−13.7 to 7.6] −8.5% [−22.9 to 0.6] Test for sex-by-race interaction P = .456
Abbreviation: CI, confidence interval; vRNA, viral ribonucleic acid.
Table 5. Types and Frequencies of Reported Clinical and Laboratory Adverse Events During the Initial 48 Weeks of the Studiesa

















Number of patients 42 102 48 477 42 102 48 477
with 1 or more AE 39 (92.9) 84 (82.4) 40 (83.3) 426 (89.3) 3 (7.1) 9 (8.8) 5 (10.4) 46 (9.6)
with drug-related AEb 15 (35.7) 35 (34.3) 12 (25.0) 154 (32.3) 0 (0.0) 4 (3.9) 1 (2.1) 16 (3.4)
with serious AEc 3 (7.1) 10 (9.8) 7 (14.6) 39 (8.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
with serious drug-related AEb 0 (0.0) 2 (2.0) 0 (0.0) 4 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
who discontinued due to AEd 0 (0.0) 3 (2.9) 1 (2.1) 7 (1.5)§ 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
who discontinued due to drug-related
AEb
0 (0.0) 1 (1.0) 0 (0.0) 4 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
who discontinued due to serious AE 0 (0.0) 3 (2.9) 1 (2.1) 4 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
who discontinued due to serious
drug-related AEb
0 (0.0) 1 (1.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
who diedc 0 (0.0) 0 (0.0) 1 (2.1) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: AE, adverse event; N, number of patients in each group; n, number (percentage) of patients in each category; n/N, frequency (%) of the stipulated AE.
a All treated patients were included in the safety analysis. All AEs occurring during the first 48 weeks of the study were tallied. The frequencies of adverse events were not adjusted for the
duration of follow up.
b Determined by investigator to be possibly, probably, or definitely drug-related to any drug in the study regimen.
c Neither of the 2 deaths were judged to be drug related.
d The discontinuations in the table refer to discontinuation of study medications (even if the patient remained in the study). One non-black man had stopped treatment but remained in the study
at week 48.
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This ﬁndingwasmore prominent with the NC= F than OFmeth-
od of handling missing data, consistent with the relatively high
drop-out rate observed among black men due to nontreatment-
related issues and thus suggesting nonvirologic reasons for the dif-
ferences. On the other hand, black men, who were the most likely
group to have baseline CD4 cell counts <50 cells/µL, experienced
the numerically greatest increment in CD4 cell counts, whereas
black women had the smallest increase.
REALMRK was a multicenter, open-label, single-arm study de-
signed with the purpose of enrolling a diverse cohort of HIV-in-
fected patients from the United States, Brazil, Dominican
Republic, Jamaica, and South Africa [18]. In contrast to our pop-
ulation, most patients were treatment-experienced. Of the 206
participants, 97 (47%) were women and 153 (74%) were black.
All received standard raltegravir-based regimens. Overall, 15%
of patients discontinued, including 13% of men, 18% of women,
14% of blacks, and 17% of non-blacks. At study week 48, response
rates were similar for men versus women and black versus non-
black patients. In contrast, there were differences observed in
drug-related clinical adverse events reported by men (8%) versus
women (18%) and blacks (14%) versus non-blacks (9%).
The limitations of our retrospective study should be explicitly
acknowledged. Although a pooled analysis was justiﬁed based
on similarities in trial design and baseline patient characteristics
in the 2 parent studies, extrapolation of these ﬁndings must be
done cautiously because subgroup analyses are inherently sub-
ject to potential bias caused by imbalances in known and unrec-
ognized covariates. Subgroups created by dividing study
participants by both sex and race had small numbers (other
than for white men); accordingly, further breakdown of the
sub-subgroups by baseline prognostic factors was not per-
formed. Patients self-identiﬁed their sex or gender and race;
patients who self-identiﬁed as multiracial were included as
non-blacks in all cases. The rationale underlying the somewhat
arbitrary categorization was that the racial components of
“multi-racial” were not collected on the case-report forms.
Self-identiﬁcation as black was thus used to assign race in our
analysis because this determination likely mimicked the
real-world perception most faithfully. Ethnicity was not differ-
entiated separately in STARTMRK. Possible confounders when
comparing sex and racial subgroups include (1) baseline vRNA
levels and CD4 counts, (2) use of prophylactic interventions for
opportunistic interventions, (3) mode of HIV acquisition and
ongoing risk behaviors, and (4) regional variation in healthcare
systems and the distribution of HIV subtypes. We did not col-
lect data on speciﬁc HIV risk factors or the likely mode of HIV
transmission. Medication adherence in black men may have
been compromised by the relatively high frequency of serious
adverse events despite their continuing in the study, although
we could not reliably conﬁrm or exclude this possibility.
Clinical trial results may not always predict real-world effec-
tiveness. The complex issues impacting the course of HIV
infection in subpopulations extend far beyond the speciﬁc
choice of antiretroviral drugs [7, 11, 12, 21–28, 30]. The interac-
tion of sex and race on the efﬁcacy and safety of treatment is
complicated by both modiﬁable and immutable covariates
such as the interplay of risk behaviors, genetic and biological
predispositions, psychosocial factors, medication access and ad-
herence, comorbidities, ethnicity and culture, country of resi-
dence, education, and socioeconomic status.
CONCLUSIONS
In our retrospective analysis, the efﬁcacy and safety of raltegra-
vir plus tenofovir-emtricitabine appeared to be generally com-
parable across sex or racial subgroups with previously untreated
HIV-1 infection. However, response rates were lower among
black men than in other subpopulations, which could be partly
explained by the higher discontinuation rates unrelated to treat-
ment in this subgroup. Strategies to mitigate treatment discon-
tinuation and suboptimal follow-up among black men in
clinical trials and in real-world practice are deserving of explicit
attention [31, 32].
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